Founded in 1992, after many years of efforts, on June 30, 2015, Wondfo was successfully listed on the GEM of Shenzhen Stock Exchange, becoming the first public company in China’s POCT industry. And today, Wondfo is developed into a promising, trusted, and socially-responsible company, with more than 3000 employees and annual revenue of 290+ million dollars in 2019.
Continuous innovation drives us forward. Wondfo has developed “Nine Technology Platforms”:
- Immune Colloidal gold Platform
- Immunofluorescence Platform
- Electrochemistry Platform
- Dry Biochemistry Platform
- Chemiluminescence Platform
- Molecular Diagnostics Platform
- Instrument Platform
- Pathology Platform
- Biological Raw Material Platform
Wondfo strives for excellence, sticks to the philosophy of "Earn everyone's trust by serving them the best", and makes every effort to meet the expectations of employees, customers, and partners.
Here, everything we do is to safeguard the health and improve the lives of people worldwide. With this in mind, we’ll continue to innovate and shape the future of POCT and healthcare.